FDA Ibutamoren Warning: Heart Failure Risk Explained
MK-677 has no FDA approval and raises congestive heart failure risk in older adults, plus higher blood sugar and insulin resistance. See the trial data.
Age V2 Mk 677
12 source-based articles maintained by the HealthRX.com Editorial Team.
12articles
3topic areas covered
Jan 28, 2025latest review
Age V2 Mk 677 library
Showing 12 of 12 clinical reviews.
MK-677 (Ibutamoren) Adolescent (12-17) Caregiver Administration Guidance
A guide for caregivers managing MK-677 (ibutamoren) use in adolescents aged 12-17, covering dosing, timing, monitoring, side effects, and when to contact a provider.
MK-677 (Ibutamoren) in Adolescents (Ages 12 to 17): Transition to Adult Care
A guide to MK-677 (ibutamoren) use in adolescents ages 12 to 17, covering growth hormone axis effects, safety concerns, and the critical steps for transitioning young patients to adult endocrine care.
MK-677 (Ibutamoren) in Adolescents Ages 12 to 17: Off-Label Use, Risks, and What the Evidence Actually Shows
A look at off-label MK-677 (ibutamoren) use in adolescents ages 12 to 17, covering growth hormone physiology, clinical trial data, safety signals, and why prescribers avoid this drug in minors.
MK-677 (Ibutamoren) in Adolescents Ages 12-17: School and Activity Considerations
What adolescents, parents, and clinicians need to know about MK-677 (ibutamoren) use during the school years, including effects on cognition, sleep, sports eligibility, and physical activity safety.
MK-677 (Ibutamoren) in Adults 65 and Older: A Clinical Transition Guide
A guide to MK-677 (ibutamoren) use in geriatric patients, covering pharmacology, dosing, risks, monitoring, and the transition from adult to geriatric care protocols.
MK-677 (Ibutamoren) in Adults 65 and Older: School, Activity, and Lifestyle Considerations
A clinical guide to MK-677 (ibutamoren) use in geriatric patients, covering physical activity compatibility, cognitive engagement, fall risk, dosing, and safety data from named trials.
MK-677 (Ibutamoren) in Children Under 12: Developmental Impact and Safety
A cautious clinical review of MK-677 (ibutamoren) and pediatric use in children under 12, covering what is and is not known about growth hormone axis effects, IGF-1 elevation, insulin sensitivity, and why no regulatory body has approved ibutamoren for this age group.
MK-677 (Ibutamoren) in Children Under 12: School and Activity Considerations
A guide covering MK-677 (ibutamoren) use in pediatric patients under age 12, including how the drug affects school performance, physical activity, sleep schedules, and growth plate safety.
MK-677 (Ibutamoren) in Children Under 12: What Parents and Clinicians Need to Know
A comprehensive review of MK-677 (ibutamoren) off-label use in pediatric patients under age 12, covering the pharmacology, clinical trial evidence, safety concerns, regulatory status, and when growth hormone secretagogues may or may not be appropriate.
MK-677 (Ibutamoren) Pediatric Administration: Caregiver Guidance for Children Under 12
A caregiver guide to MK-677 (ibutamoren) in children under 12, covering safety data, dosing considerations, regulatory status, and when to contact a prescriber.
MK-677 (Ibutamoren) Pediatric Transition to Adult Care: What Clinicians and Families Need to Know
A clinician-focused guide to transitioning pediatric patients under age 12 who have received MK-677 (ibutamoren) into adult GH-axis care protocols, covering safety data, regulatory status, dosing, and monitoring frameworks.